Intrinsic Therapeutics Announces the Enrollment of the 400th Patient in Landmark Barricaid® Randomized Trial
Woburn, MA. July 31, 2013—Intrinsic Therapeutics today announced the enrollment of the 400th patient in a level 1, prospective, randomized, multi-center clinical trial evaluating the effectiveness of its Barricaid Prosthesis in improving outcomes for lumbar discectomy patients suffering from sciatica. The surgery was performed by Dr. Frederic Martens in Aalst, Belgium. The study is being conducted in Germany, Switzerland, Austria, and The Benelux with the goal of demonstrating fewer disc reherniations and improved function in high-risk patients treated with the Barricaid compared to limited discectomy only.Read on »
Barricaid® iPad App Now Available Through iTunes Store!
Barricaid Surgical Training application (App) for the iPad is now available to download free of charge from the iTunes App Store. The app is designed to support user training and provide reference for Intrinsic Therapeutics’ Barricaid®, Prosthesis for Partial Anulus Replacement, and its accompanying system for replacing missing or damaged parts of the posterior anulus fibrosus in intervertebral lumber discs.The app is designed to support user training and provide reference for Intrinsic Therapeutics’ Barricaid®, Prosthesis for Partial Anulus Replacement, and its accompanying system for replacing missing or damaged parts of the posterior anulus fibrosus in intervertebral lumber discs. Use of the applications will provide surgeons with hands-on preoperative and intraoperative procedural guidance and training for proper clinical treatment using the Barricaid system. We greatly appreciate any feedback on lay-out, ease of use, functionality, descriptions etc. Currently, the app is only available in iPad format and will not show up if searching on an iPhone.Read on »
Partial Anulus Replacement with Barricaid® Prosthesis
3rd January 2013 – discectomies often only result in a short-term success. An aggressive removal of the nucleus increases the risk of a collapse of the intervertebral disc. Whereas a carefully limited discectomy could lead to an increased risk of reherniation. The Barricaid® Prosthesis for anular closure closes the anular defect, thus enabling the nucleus to be largely preserved. Specialists from various disciplines, attending a symposium organised by Intrinsic Therapeutics as part of the 7th Annual Meeting of the German Spine Society, discussed to what extent Barricaid® can sustainably prevent reherniations as well as preserving the intervertebral disc height and hence the biomechanics.
Read on »
Intrinsic Therapeutics Announces Enrollment of 300th Patient in Barricaid® Randomized Trial
Intrinsic Therapeutics, a Medical Device Spine company, today announced a key milestone in a clinical study of its Barricaid® Prosthesis: 300 patients are now enrolled in a prospective, randomized, multi-center trial to definitively establish the safety and effectiveness of the implant. This Level 1 controlled study is being conducted across five countries in Europe and is expected to include 400-650 patients.
Read on »
Intrinsic at the Annual Meeting of the German Society of Neurosurgery (DGNC)
Barricaid® Prosthesis for Anular Closure is an important thematic focal point of the 63rd Annual Meeting of the German Society of Neurosurgery. On June 16, 2012, 4 papers dealing with the clinical results of Barricaid were presented, which include, among others, 2-year results coming from a multinational clinical study. Read on »
Intrinsic Therapeutics, Inc. Names Cary P. Hagan as President & CEO
Intrinsic Therapeutics, a medical device company focused on developing therapies to address the spine market’s many unmet needs, today announced that Cary Hagan has been appointed President and Chief Executive Officer. Mr. Hagan brings over 20 years of experience in the orthopedic implant field with significant expertise in product development, commercialization and global marketing strategy. Greg Lambrecht, Founder and Board Member of Intrinsic, is actively continuing at the company as Executive Director Read on »